Pages that link to "Q42164889"
Jump to navigation
Jump to search
The following pages link to From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis (Q42164889):
Displaying 50 items.
- The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials. (Q33208464) (← links)
- Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis (Q33403831) (← links)
- Development and analyses of evaluation criteria for meta-analysis-relationship between renin-angiotensin system inhibitor and diabetes mellitus (Q33686761) (← links)
- Effects of immunoadsorption on endothelial function, circulating endothelial progenitor cells and circulating microparticles in patients with inflammatory dilated cardiomyopathy (Q33813731) (← links)
- Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome (Q33840829) (← links)
- ACE inhibition reduces infarction in normotensive but not hypertensive rats: correlation with cortical ACE activity (Q34171310) (← links)
- Antiatherogenic properties of flavonoids: implications for cardiovascular health. (Q34618665) (← links)
- Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis (Q34774221) (← links)
- The practical aspects of combination therapy with angiotensin receptor blockers and angiotensin-converting enzyme inhibitors (Q34849485) (← links)
- Vascular and cardiac benefits of angiotensin receptor blockers (Q34980898) (← links)
- Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril (Q35014556) (← links)
- The vulnerable plaque and acute coronary syndromes (Q35035390) (← links)
- Heart failure and the brain: new perspectives (Q35046024) (← links)
- Contribution of angiotensin-(1-7) to cardiovascular physiology and pathology (Q35087012) (← links)
- Obesity-associated activation of angiotensin and endothelin in the cardiovascular system. (Q35099135) (← links)
- Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold? (Q35154540) (← links)
- Diabetic renal disease: from recent studies to improved clinical practice (Q35620727) (← links)
- Clinical experience with angiotensin receptor blockers with particular reference to valsartan (Q35861992) (← links)
- Dual blockade of the renin angiotensin system in diabetic and nondiabetic kidney disease (Q35876449) (← links)
- Antihypertensive medications for risk reduction of first and recurrent ischemic stroke (Q35925696) (← links)
- Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system (Q35933720) (← links)
- Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan (Q36014340) (← links)
- Inflammation, blood pressure, and stroke: an opportunity to target primary prevention? (Q36025929) (← links)
- Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence (Q36210252) (← links)
- Antihypertensive drugs and incidence of type 2 diabetes: evidence and implications for clinical practice (Q36255398) (← links)
- Protective effects of angiotensin II interruption: evidence for antiinflammatory actions (Q36257966) (← links)
- Management of patients with type 2 diabetes after acute coronary syndromes (Q36333931) (← links)
- Blood pressure control and prevention of stroke (Q36390821) (← links)
- Drug Insight: angiotensin-converting-enzyme inhibitors and atrial fibrillation--indications and contraindications (Q36433583) (← links)
- Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a review of the current evidence. (Q36480076) (← links)
- Valsartan in the treatment of heart attack survivors (Q36744015) (← links)
- Renin: friend or foe? (Q36815446) (← links)
- Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update (Q36842353) (← links)
- The role of angiotensin II type 1 receptor blockers in the prevention and management of diabetes mellitus (Q36909521) (← links)
- Regulation of the renin-angiotensin system in coronary atherosclerosis: a review of the literature (Q37058920) (← links)
- Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy (Q37064847) (← links)
- Characteristics of patients prescribed angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the combination at an urban medical center (Q37098630) (← links)
- Direct renin inhibition: clinical pharmacology (Q37119806) (← links)
- Risk factor management to prevent first stroke (Q37153566) (← links)
- Anti-hypertensive drugs and left ventricular hypertrophy: a clinical update (Q37756022) (← links)
- Direct renin inhibition: from pharmacological innovation to novel therapeutic opportunities (Q37939271) (← links)
- Heart failure in hypertension: prevention and treatment (Q38022713) (← links)
- Organometallic aspects of transition-metal catalysed regioselective C-H bond functionalisation of arenes and heteroarenes. (Q38178035) (← links)
- Angiotensin II and trials of cardiovascular outcomes (Q42164880) (← links)
- Angiotensin II subtype AT1 receptor blockade prevents hypertension and renal insufficiency induced by chronic NO-synthase inhibition in rats (Q44367473) (← links)
- Review: Potential of renin inhibition in cardiovascular disease (Q44401588) (← links)
- Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension (Q44745545) (← links)
- Results of the VALIANT trial in post-myocardial infarction (Q44981474) (← links)
- Renin inhibition with aliskiren (Q46727866) (← links)
- Synthesis of substituted indolizines via radical oxidative decarboxylative annulation of 2-(pyridin-2-yl)acetate derivatives with α,β-unsaturated carboxylic acids (Q48958589) (← links)